Skip to main content

Interactions between Palifermin and Tecvayli

1 drug interaction and 3 additional warnings found for the following 2 drugs:

Add/remove drugs

Drug interactions

Moderate drug interactions

Moderate:

palifermin teclistamab

Applies to: palifermin and Tecvayli (teclistamab)
Adjust dosing interval

In a clinical trial, administration of palifermin within 24 hours of chemotherapy resulted in increased severity and duration of oral mucositis, presumably due to increased sensitivity of the rapidly dividing epithelial cells in the immediate post-chemotherapy period.

Management

Palifermin should not be administered within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.

References (1)
  1. (2004) "Product Information. Kepivance (palifermin)." Shire US Inc

Food/lifestyle interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Disease interactions

3 potential interactions Applies to: 3 conditions, including Liver Disease, Infection, and Renal Dysfunction.

Infection

Moderate:

Tecvayli

The teclistamab in Tecvayli has a moderate potential interaction with Infection.

Teclistamab and talquetamab can cause severe, life-threatening, or fatal infections. Patients should be monitored for signs and symptoms of infection prior to and during treatment. Any infection should be treated appropriately. Administer prophylactic antimicrobials according to clinical guidelines.

Liver Disease

Moderate:

Tecvayli

The teclistamab in Tecvayli has a moderate potential interaction with Liver Disease.

The effects of severe renal impairment (eGFR less than 30 mL/min) on the pharmacokinetics of teclistamab and talquetamab are unknown. Moderate to severe hepatic impairment (total bilirubin greater than 1.5 times ULN with any AST) on the pharmacokinetics of teclistamab are unknown. Severe hepatic impairment (total bilirubin greater than 3 times ULN with any AST) on the pharmacokinetics of talquetamab are unknown. Additionally, teclistamab and talquetamab have caused hepatotoxicity, including fatalities. Caution is advised in patients with renal and hepatic impairment. Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated.

Renal Dysfunction

Moderate:

Tecvayli

The teclistamab in Tecvayli has a moderate potential interaction with Renal Dysfunction.

The effects of severe renal impairment (eGFR less than 30 mL/min) on the pharmacokinetics of teclistamab and talquetamab are unknown. Moderate to severe hepatic impairment (total bilirubin greater than 1.5 times ULN with any AST) on the pharmacokinetics of teclistamab are unknown. Severe hepatic impairment (total bilirubin greater than 3 times ULN with any AST) on the pharmacokinetics of talquetamab are unknown. Additionally, teclistamab and talquetamab have caused hepatotoxicity, including fatalities. Caution is advised in patients with renal and hepatic impairment. Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated.

Report options

Loading...
QR code containing a link to this page

More resources

palifermin

A total of 128 drugs are known to interact with palifermin.

Tecvayli

A total of 445 drugs are known to interact with Tecvayli.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer